Most Recent Articles by Jody A. Charnow, Editor
Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
More Articles by Jody A. Charnow, Editor
Renal and Urology News Articles
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer
- Dialysis and Transplant Patients at Increased Risk for Cancer Death
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)